Stockwinners Market Radar for April 05, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EDT Cathie Wood's ARK Investment bought 229K shares of Twist Bioscience today

19:00 EDT GAP Airports reports March 2022 passenger traffic up 10.2% vs March 2019 - GAP Airports announced preliminary terminal passenger traffic figures for the month of March 2022, which includes comparisons with the 2019 and 2021 figures to facilitate the reading and understanding of the passenger traffic trend. For March 2022, the total number of terminal passengers at GAP's 12 Mexican airports increased by 11.7%, compared to the same period of 2019. Tijuana, Los Cabos, Puerto Vallarta and Guadalajara airports presented an increase in passenger traffic of 37.1%, 17.7%, 6.6% and 0.9%, respectively.

18:20 EDT West Fraser Timber to permanently reduce capacity at pulp mill in Hinton - West Fraser Timber Co. announced that it will permanently reduce capacity at its pulp mill in Hinton, Alberta by the end of this year. One of Hinton Pulp's two production lines will shut, and the remaining line will produce Unbleached Kraft Pulp rather than Northern Bleached Softwood Kraft Pulp. "Hinton Pulp has been in operation since 1956 and these changes are necessary to simplify our operation, reduce capital requirements and greenhouse gas emissions, and better align with consumer expectations," said Ray Ferris, President & CEO, West Fraser. The capacity reduction will see staffing levels transition from 345 positions to 270. West Fraser expects to mitigate the impact on employees through natural attrition, retirements and by offering employment opportunities at other West Fraser operations. As the world moves away from single-use plastics, UKP is now used increasingly in a wide variety of everyday items including cardboard packaging, grocery bags, fibre-cement board and specialty products. Since late 2021, the mill has undertaken several product trials and received positive initial customer feedback as to the quality and strength of the pulp produced. Currently, mill employees are preparing for the transition after satisfying all existing customer commitments for NBSK. It is anticipated that an impairment charge of approximately $13M will be recorded in West Fraser's first quarter 2022 results associated with the write-down of equipment that will be decommissioned permanently as part of the transition to UKP.

18:03 EDT IBM debuts the IBM z16 its 'next-generation mainframe system' - IBM stated in a blog post earlier: "Today, we're unveiling IBM z16, our next-generation mainframe system, containing several groundbreaking innovations, including the new 7 nm Telum chip that can facilitate on-device AI inferencing that's 20 times faster than sending an AI request to an x86 server in the cloud, as well as quantum-safe cryptography, multi-cloud support, and data privacy that's central to the system. Many of those innovations began life in IBM Research. These innovations didn't happen overnight. Back in 2015, IBM Research demonstrated the industry's first 7 nm test chip with our partners, including Samsung. This 7 nm technology achieved two important milestones: 2.4x logic density and 17.6% frequency gain over 14 nm technology, which was at that time the most advanced technology. This 7 nm chip included the first implementation of Extreme UltraViolet (EUV) lithography technology. We had developed the semiconductor technology that would provide a foundation for better performance and power saving." Reference Link

17:55 EDT MongoDB CFO sells $3.1M in common stock - In a regulatory filing, MongoDB disclosed that its CFO Michael Gordon sold 6.9K shares of common stock on April 4th in a total transaction size of $3.1M, reducing his stake by about 6%.

17:46 EDT Gol Linhas reports preliminary March ASK up 93% - Gol Linhas announced preliminary air traffic figures for the month of March 2022, compared to the same period in 2021. GOL's total supply increased 93.0%. Total seats increased 100.5% and the number of departures increased by 101.5%. GOL's total demand increased by 113.9% and the load factor was 79.5%. GOL's domestic supply increased 86.1% and demand increased by 106.4%. GOL's domestic load factor was 79.6%. The volume of departures increased by 98.0% and seats increased by 97.1%. GOL's international supply was 111 million, the demand (RPK) was 87 million and international load factor was 78.0%.

17:21 EDT PS Business Parks names Stephen Wilson as CEO, effective immediately - PS Business Parks (PSB) announced today that Stephen Wilson has been appointed as the company's President and CEO, effective immediately. Wilson has been serving as interim President and CEO since January 17. Wilson has been a director of the company since July 2019 and will continue to serve as a director. Wilson was Executive Vice President-Development of AvalonBay Communities (AVB) from 2014 until his retirement in 2019.

17:19 EDT Twitter revises its Ukraine policy to 'de-amplify' certain tweets, PoW imagery - In an update to its Ukraine blog, which was first published on 16 March, Twitter's VP of Global Public Policy, Sinead McSweeney, said in part: "This blog was first published on 16 March 2022, and last updated 5 April 2022 to include updates to our policy approach and metrics on the impact of our work. Like so many around the world, we're disturbed and deeply saddened by the Russian invasion of Ukraine and the humanitarian crisis unfolding there. Our top priority is to promote the safety of people on and off the service, and our teams are working diligently to that end...Over the past several weeks, people in Ukraine, Russia, and around the world have used Twitter to share critical information in real-time, locate support, connect with one another, and raise their voices. Unfortunately, we are also aware that Twitter is being restricted for some people in Russia....If content is in violation of the Twitter Rules, we'll take enforcement action against it at the Tweet or account level - this includes content removal...We are labeling qualifying government accounts to provide additional context. We'll be rolling out government account labels to Ukrainian government accounts...we will not amplify or recommend government accounts belonging to states that limit access to free information and are engaged in armed interstate conflict - whether Twitter is blocked in that country or not..To that end, we will now ask government or state affiliated media accounts to remove any media published that features prisoners of war, PoW, under our private information and media policy." Reference Link

17:07 EDT Valens issues letter to shareholders regarding recent financing - Valens released the following letter to shareholders from the company's CEO, Tyler Robson, and president, Jeff Fallows outlining the rationale for the recent financing. The company said, "As you have seen, we launched and closed a bought deal financing for gross proceeds of US$28.75 million (the "Financing"), which included the exercise in full of the underwriters' overallotment option, through a syndicate of underwriters led by Stifel GMP and AGP. The decision to pursue this Financing was not taken lightly. As shareholders ourselves, and stewards for capital invested by other shareholders, any issuance of equity capital is approached with caution and must only occur based on a compelling rationale and a belief that the issuance will improve the potential for us to increase shareholder value in the future. We wanted to take this opportunity to provide this rationale and clearly articulate why we believe this action was in the best interest of our shareholders. The Canadian cannabis legal reforms have provided a once-in-a-lifetime social and financial opportunity to build a new consumer products industry but the challenges currently facing the sector are real. Companies with innovative products and the financial flexibility to execute against their strategic focus are best positioned to survive these challenges and be the leaders of the industry who will benefit in future years to come. The rationale for the Financing includes the following: Managing Working Capital and Cash Cycles: As demonstrated by our Q4 2021 performance, we have successfully transitioned into a branded B2C company, with almost 75% of our revenue coming from this category. We have seen very strong success in growing market share in Canadian provincial sales as demonstrated by the growth of our flower brands including Versus, Contraband, and Citizen Stash. As of March 2022, we have the #1 best-selling flower SKU, in BC God Bud, across all product categories in the first three months of 2022, despite not cultivating cannabis flower ourselves. As discussed on numerous occasions, we do not believe that owning cultivation assets in an oversupplied environment is an effective strategy. However, our asset light strategy has required a higher working capital investment over the last few quarters to cover the cash cycles needed to purchase targeted strains on the spot market. More specifically, we have had to purchase biomass for cash up front and have typically experienced a minimum 90-day cash conversion cycle to provincial revenue. In addition, we have also increased our investment into inventory to reduce stockouts for our core brands which continue to experience rapid growth. As we have launched new brands and new products it has caused, and is expected to continue to cause, some near-term volatility in inventory balances. However, we expect investment in inventory to stabilize by Q4 2022, as consumer demand and purchase orders of our products achieve a more normalized level of sell-through and lead to tighter inventory management. In addition, we are in the process of executing new contract grow arrangements and tightening our accounts payable and accounts receivable cycles to optimize cash management for the business. However, at this time further capital was required to ensure we meet growing demand. Financial Flexibility: The 'Integration Initiatives' and decisions we have made over the last 90-days are expected to positively impact our cost structure in the second half of the year. At the same time, ongoing inflationary cost pressures, a volatile supply chain, and heightened geopolitical risk are not expected to ease in the near term. Faced with this reality, we took steps necessary to strengthen our balance sheet and provide additional financial support to our business until the benefits of our 'Integration Initiatives' are realized, and our operating environment normalizes. As we continue to broaden institutional and public reach initiatives, we are pleased to inform our shareholders that the Financing was led by a CPG-focused US institutional investor and included both Canadian and US institutions. Growth Initiatives: We are evaluating two strategic areas for potential investment in 2022: Internalizing Manufacturing at Green Roads: While Green Roads maintains a strong portfolio of cGMP manufacturing capabilities, there are nevertheless opportunities to bring additional expertise in-house. This remains in-line with the opportunities for synergies we saw when analyzing the acquisition and provides an additional opportunity for Valens to leverage its Canadian-based innovation expertise south of the border. Several of our outsourced products have been subject to manufacturing variability and stockouts which can be addressed in the near and medium term through both partner optimization and investment in our internal capabilities. Discounted Assets: We have committed to our shareholders that our first priority in 2022 is to integrate previous acquisitions and to right size our cost structure before pursuing any additional acquisitions. As we continue to make progress on this objective, we will become increasingly opportunistic to take advantage of the growing number of attractive assets in both the US and Canada which are hitting the market at significantly discounted prices."

17:00 EDT JetBlue trading resumes

16:54 EDT Rivian Automotive reports Q1 production of 2,553 vehicles - Rivian Automotive "announced production totals for the quarter ending March 31, 2022. The company produced 2,553 vehicles at its manufacturing facility in Normal, Illinois and delivered 1,227 vehicles during the same period. These figures are in line with the company's expectations, and it believes it is well positioned to deliver on the 25,000 annual production guidance provided during its fourth quarter earnings call on March 10, 2022."

16:51 EDT JetBlue to resume trading at 17:00ET

16:49 EDT Riot Blockchain reports March Bitcoin production up roughly 176% y/y - Riot Blockchain announced production and operations update for March 2022, status of miner shipments and deployment, and updates on the 400 megawatt infrastructure expansion at the company's Whinstone US, Inc., facility in Rockdale, Texas. "I am proud of the Riot team for producing a record amount of Bitcoin during the month of March," said Jason Les, CEO of Riot. "These results demonstrate the advantages of employing a vertically integrated strategy, which provide the Company with more control over miner deployment and the ability to implement engineering solutions in real-time, leading to improved operational and financial efficiencies." In March 2022, Riot produced 511 BTC, an increase of approximately 176%, as compared to March 2021 production of 185 BTC. Riot currently has a deployed fleet of approximately 42,919 miners, with a hash rate capacity of 4.3 exahash per second.

16:47 EDT Tivic Health appoints Veronica Cai as CFO - Tivic Health announced executive appointments. Veronica Cai has joined the company as chief financial officer effective April 1 and Ryan Sabia was promoted to chief operating officer in December 2021. Prior to joining the company, Cai was vice president of accounting and finance at RefleXion Medical.

16:20 EDT Spirit Airlines confirms receipt of unsolicited buyout proposal from JetBlue - Spirit Airlines (SAVE) announced that it has received an unsolicited proposal from JetBlue Airways (JBLU) to acquire all of the outstanding shares of Spirit's common stock in an all-cash transaction for $33.00 per share. Consistent with its fiduciary duties, the Spirit Board of Directors will work with its financial and legal advisors to evaluate JetBlue's proposal and pursue the course of action it determines to be in the best interests of Spirit and its stockholders. The Board will conduct this evaluation in accordance with the terms of the company's merger agreement with Frontier (ULCC) and respond in due course. Spirit shareholders do not need to take any action at this time.

16:17 EDT JetBlue trading halted, news pending

16:12 EDT Athira Pharma sends letter to shareholders ahead of annual meeting - Athira Pharma announced that it has filed its definitive proxy statement with the Securities and Exchange Commission for its upcoming annual meeting of shareholders scheduled to be held on May 19. Shareholders of record as of March 21 will be entitled to vote at the meeting. In connection with the definitive proxy filing, Athira is mailing a letter to shareholders. The company summarized the letter as follows: "Athira's leadership team is executing effectively against the company's strategic priorities and poised to report topline results from the Phase 2 ACT-AD study by the end of the second quarter of 2022. Athira is well capitalized and advantageously positioned to execute key objectives with cash on hand to fund the organization through multiple upcoming clinical milestones, including receipt of topline data for the ACT-AD, LIFT-AD and SHAPE trials. Athira has systematically and thoughtfully added experience and expertise to its board in support of advancing its strategy. The company's director nominees have the right skills and experience needed to support Athira at this critical time. Richard A. Kayne's platform is misguided and unnecessarily disruptive, and he and his nominee would not add skills or expertise that are not already well represented by the company's highly qualified, independent directors. Athira has attempted to engage constructively with Mr. Kayne to reach an amicable resolution that would enable the board and leadership to direct their resources and focus on the execution of the company's clinical trials, instead of a costly, distracting proxy contest. Mr. Kayne has rejected Athira's attempts to find common ground. The board of directors is confident that Athira has the right strategy and the right leadership team to continue positioning the company for success."

16:08 EDT Amazon, Arianespace sign contract for 18 Ariane 6 launches - Arianespace has signed a contract with Amazon for 18 launches of the Ariane 6 launcher to put the Kuiper constellation of satellites for broadband internet into orbit. This is the largest agreement so far signed by the consortium that markets European launches. Amazon's project aims to connect the disconnected by providing high-speed, low-latency broadband to unserved and underserved communities around the world at affordable prices. Homes, schools, hospitals, businesses, governments and institutions that do not have access to connectivity will soon have it through the Kuiper project. The launcher that will be used is the Ariane 64, the heavy version of the new Ariane 6, equipped with four P120C motors, developed by Avio, which will be the solid rocket boosters. In particular, for 16 of the 18 Kuiper launches, the rocket will be equipped with an enhanced version of the P120C, called the P120C+. This new development, funded by ESA, will see Avio committed to increasing the performance of the motors, which will allow for a significant increase in payload capacity for Ariane 6. Production activities in the coming years will have to ensure rapid deployment of the Kuiper constellation. At the same time, the P120C+ will also be used for Vega C, which uses the same motor as first stage, thus increasing payload capacity and the rocket's versatility, expanding launch solutions for commercial and institutional customers.

16:07 EDT Afya acquires CardioPapers for R$35M - Afya Limited announced the acquisition, through its wholly-owned subsidiary Afya Participacoes S.A., of 100% of CardioPapers. CardioPapers had 7,000 students in 2021 and almost 215,000 followers on Instagram. The company expects R$18.8M of gross revenue for 2022. The aggregate purchase price paid to sellers was R$35M, of which 100% was paid in cash. An earn-out of up to R$15M can be paid, R$14M related to revenue goals and R$1M related to other goals, both established for 2023 and 2024.

16:03 EDT Array Technologies appoints Kevin Hostetler as CEO - Array Technologies announced that Kevin Hostetler has been appointed CEO, effective April 18. Hostetler will also join Array's board of directors. He succeeds Jim Fusaro, who previously announced his intention to retire by the end of the year. Hostetler most recently served as CEO at Rotork, a FTSE 250 company, where he led the company's growth acceleration program.

15:49 EDT Spirit Airlines trading halted, news pending - The halt follows the New York Times' report that JetBlue Airways (JBLU) has made an offer to acquire Spirit Airlines (SAVE) for roughly $3.6B, or $33 per share in cash.

15:43 EDT Spirit Airlines trading resumes

14:19 EDT Black Knight trading resumes

14:15 EDT Black Knight jumps 6% to $62.60 after Bloomberg report of takeover interest

14:01 EDT AIkido Pharma announces strategic investment in MasterClass - AIkido Pharma announced that the company has secured an early equity interest in privately-held Yanka Industries, doing business as MasterClass. MasterClass is self-described as the "streaming platform where the world's best come together so anyone, anywhere, can access and be inspired by their knowledge and stories." Anthony Hayes, CEO of Aikido, stated, "The extraordinary content provided by MasterClass truly reflects its name. We are amazed by the broad spectrum of topics and sheer number of prominent and renowned experts who have recorded the lectures provided by MasterClass's service. We are thrilled to be a part of this exceptional company, especially considering the potential it provides for value creation for our shareholders. As some sectors of the market begin to slow down, we are constantly looking for opportunities that will augment shareholder value."

13:51 EDT Square Enix's next 'Tomb Raider' game to be built using Unreal Engine 5 - Square Enix (SQNXF) said that its Crystal Dynamics studio is working on a new "Tomb Raider" game, which will be built using Epic's Unreal Engine 5. Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony (SONY). Reference Link

13:44 EDT Twitter founder Dorsey says wanted Tesla's Musk on board 'for a long time' - Twitter's co-founder and former CEO Jack Dorsey stated in a reply to a tweet: "I've wanted Elon on the board for a long time" Reference Link

13:14 EDT Meta Platforms introduces Sharing to Reels - Meta Platforms' John McCarthy stated in a blog post: "Enabling Sharing to Reels makes it easy for people to share short-form videos directly to Facebook. Once integrated, third-party apps will have a Reels button so people can share short videos, then customize with Reels editing tools like audio, text, effects, captions and stickers. Instead of downloading their video content and uploading it later, they can now create and share video seamlessly with one tap of a button. Reels is our fastest growing content format, now available in more than 150 countries across the globe. We're focused on making Reels the best way for creators to get discovered, connect with their audience and earn money. We also want to make it fun and easy for people to find and share relevant and entertaining content... As part of this launch, we're excited to highlight partners like Smule, Vita, and VivaVideo who have integrated #SharingtoReels and are finding new ways for Creators to express themselves, grow their communities and reach new audiences." Reference Link

12:11 EDT Cassava Sciences drops after update on Alzheimer's drug studies - Shares of Cassava Sciences are down $4.89, or 13%, to $33.58 near midday after the company stated during a webcast that 60 subjects have now been dosed in its Phase 3 studies out of the "about 1,750 patients" that the company is is looking to recruit for its Phase 3 program to study Simufilam in patients with mild to moderate Alzheimer's disease. In Cassava Sciences' "first fireside chat for 2022," the company's CFO Eric Schoen and CEO Remi Barbier offered answers to 20 questions they had received by email from stakeholders. The studies opened roughly six months ago, in which time Cassava has managed to recruit 3% of the patients it needs to complete the Phase 3 program, the comments from the event held earlier indicate. The company's call script quotes Barbier as having said on the call: "I think it's too soon to project enrollment rates for the Phase 3 studies. I would expect to see a steady enrollment rate we have all 175 clinical trial sites activated. As a reminder, Phase 3 studies do take a long time to complete. Waiting for data is a vital part of our business. This is appropriate because whatever data we generate in the Phase 3 program will determine the fate of the drug at the FDA." Reference Link

12:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -13.6% - ProShares UltraShort Bloomberg Natural Gas is down -13.6%, or -$2.12 to $13.48.

12:00 EDT Enovis falls -42.4% - Enovis is down -42.4%, or -$49.69 to $67.49.

12:00 EDT Dingdong rises 27.0% - Dingdong is up 27.0%, or $1.27 to $5.97.

11:51 EDT Northrop Grumman, AT&T announce collaboration agreement - Northrop Grumman (NOC) and AT&T (T) announced they have entered into a collaboration agreement to research and develop a digital battle network, powered by AT&T 5G and Northrop Grumman's advanced mission systems, to support the U.S. Department of Defense. "The agreement establishes a joint research and development framework to prototype, demonstrate and test AT&T's commercial 5G networking capabilities integrated with Northrop Grumman's robust portfolio of capabilities that are at the forefront of military technological advancement that enable the Joint Force," the companies stated.

11:24 EDT Aziyo Biologics Inc trading resumes

11:03 EDT Mattel appoints Steve Totzke as president - Mattel has promoted Steve Totzke to President and Chief Commercial Officer of the Company. Since being named EVP and CCO in 2018, Totzke has been responsible for driving Mattel's growth in markets worldwide and overseeing Mattel's unified global commercial organization

10:35 EDT Bristol-Myers announces EC approval for Breyanzi for certain types of lymphoma - Bristol Myers Squibb announced that the European Commission has granted Marketing Authorization for Breyanzi, a CD19-directed chimeric antigen receptor T cell immunotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, primary mediastinal large B-cell lymphoma, or PMBCL, and follicular lymphoma grade 3B, or FL3B, after two or more lines of systemic therapy. The Marketing Authorization approves Breyanzi for use in all European Union (EU) member states, the company noted.

10:03 EDT Alta Fox files proxy statement in connection with Hasbro annual meeting - Alta Fox Capital Management, the beneficial owner of approximately 2.5% of the outstanding shares of Hasbro, announced that it has filed a preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with its nomination of five candidates for election to the Company's Board of Directors at the 2022 Annual Meeting of Shareholders. Connor Haley, Managing Partner of Alta Fox, commented: "Following an extensive review of Hasbro's business segments, capital allocation decisions, corporate governance, executive compensation and historical performance, we have concluded that the Company is a chronic underperformer that trades at a significant discount to its intrinsic value due to a poorly executed "Brand Blueprint" strategy and various correctable issues. It is clear to us that shareholder-driven change in the boardroom is needed to restore accountability and put Hasbro back on a path to long-term value creation. While the incumbents believe they are doing a stellar job, the reality is Hasbro's share price is lower today than it was five years ago and is currently trading near its 52-week low. It is important to stress that we have spent months trying to engage with the current Board to avert an election contest and reach a reasonable compromise that could catalyze the right degree of change at Hasbro. Unfortunately, we have found the Board to be deeply entrenched, insular and in denial about the Company's needs and the value of shareholder input. This was exemplified by the Board's decision to refuse Alta Fox's settlement framework that included the appointment of just one of our nominees to the Board. We note that most of the Board, including Chairman Rich Stoddart, was nominated during Alan Hassenfeld's tenure, leading us to conclude that it lacks the objectivity to properly evaluate the Company's historical performance and strategy. While we acknowledge the apparent gaming credentials of Hasbro's recently added directors, we contend the Company needs additional change to fix the numerous issues at hand. Given that roughly 70% of the Company's value stems from its Wizards of the Coast gaming division, we believe additional gaming experience and other skillsets are needed in the boardroom. We are also concerned by the Company's seemingly defensive and reactionary decision to expand the Board from 11 directors to 13 directors and believe that shareholders will see through what appears to be the Company's hollow commitment to reduce the size of the Board in the coming years. We are confident our slate of five highly qualified and independent nominees possesses the right mix of gaming and technology experience, capital markets expertise, corporate governance knowhow and ownership perspectives. Alta Fox will continue to advocate for its slate and shareholders' best interests, and looks forward to providing investors the opportunity to vote for a better Hasbro."

10:00 EDT ProShares UltraShort Bloomberg Natural Gas falls -8.4% - ProShares UltraShort Bloomberg Natural Gas is down -8.4%, or -$1.32 to $14.28.

10:00 EDT Enovis falls -48.4% - Enovis is down -48.4%, or -$56.69 to $60.49.

10:00 EDT Dingdong rises 21.9% - Dingdong is up 21.9%, or $1.03 to $5.73.

09:57 EDT Trebia Acquisition Corp trading resumes

09:51 EDT 180 Degree Capital portfolio company TARA Biosystems acquired by Valo Health - 180 Degree Capital Corp. noted that its legacy private portfolio holding, TARA Biosystems, Inc., has been acquired by Valo Health. Under the terms of the acquisition, 180 will receive approximately $2.7 million in cash over the next 24 months and has the potential to receive an additional $3.3 million upon achievement of certain milestones.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -7.6% - ProShares UltraShort Bloomberg Natural Gas is down -7.6%, or -$1.18 to $14.42.

09:47 EDT BRC Inc. falls -9.1% - BRC Inc. is down -9.1%, or -$2.56 to $25.72.

09:47 EDT Sunlands Online rises 12.9% - Sunlands Online is up 12.9%, or 60c to $5.25.

09:38 EDT Stephen Cloobeck demands Playstudios replace CEO, management - Stephen Cloobeck, a substantial shareholder in Playstudios, released a letter to the Company's Board of Directors advocating for the removal of Chairman and CEO Andrew Pascal and his management team. The letter read in part, "I write on behalf of myself, as a substantial shareholder of Playstudios, as well as fellow shareholders who like me are frustrated with the direction of the Company under its current management. I implore you to take immediate action and replace Chairman and Chief Executive Officer Andrew Pascal and his management team before shareholder value is eroded further than it has been already. Under Mr. Pascal, the company has proven time and again that it overpromises and underdelivers on critical product, revenue, and profit goals. Is it any wonder the company's stock has not only underperformed the market, but also its closest competitors? One commentator called Playstudios "One of the Worst-Performing De-SPACed Companies Over Past Year," and that was last August, before the stock plummeted even further. Another, more recently in February, wrote a commentary titled, "Getting Played By Playstudios." Not exactly a public vote of confidence in management. I and other shareholders are also curious, and the SEC might be too, about how Mr. Pascal profited by selling high into last year's SPAC transaction, then proceeded to miss revenues and lower guidance right out of the gate, cratering the stock. Now, with the stock scraping the bottom thanks to Mr. Pascal's mismanagement of the company, he is a buyer again at prices ranging from $4 to $5. Has the Board taken any measures to ensure that he is not trading on privileged information that other shareholders are lacking?...As noted above, this is just a summary but by no means the only examples of the mismanagement under Mr. Pascal and his team. He has fumbled on execution and shareholders are paying the price. I am writing to the Board because it is your responsibility to assess the overall direction and strategy of the business and supervise and evaluate the CEO. I believe the facts show that Mr. Pascal has not performed. I am writing to request that the Board do the right thing and replace Mr. Pascal with someone who can restore confidence that this Company is on a path for success."

09:33 EDT Phunware says PhunToken now available on Uniswap - Phunware announced that PhunToken is now available on Uniswap. Ecosystem participants leveraging Uniswap will need to use the PhunToken Contract Address in order to import PHTK as a new custom token before initiating any swap, while PHTK will remain available for direct purchase on the PhunToken Buy Portal with US Dollars, Bitcoin or Ethereum.

09:28 EDT Core Scientific appoints Denise Sterling CFO, has 80K bitcoin miners as of March - The Company announced that Denise Sterling, Senior Vice President of Finance, has been appointed to the role of Chief Financial Officer and will be moving to the Austin, TX headquarters later this year. Former CFO Michael Trzupek will leave the company to pursue new opportunities after a transition period. Core Scientific's self-mining operations produced 1,143 bitcoins in March, averaging 36.9 bitcoins per day, an increase from February's daily average of 35. As of March 31, 2022, the Company held 8,497 bitcoins produced from operations. As of March month end, Core Scientific operated its own fleet of more than 80,000 bitcoin miners, producing 8.3 EH/s.

09:26 EDT Gogoro debuts on Nasdaq - Gogoro became a publicly listed company trading on the Nasdaq Global Select Market with its ordinary shares and warrants listed under the new ticker symbols "GGR" and "GGROW", respectively. Gogoro completed the previously announced merger with Poema Global on April 4. The combined company will now operate as Gogoro.

09:24 EDT MicroStrategy acquired 4,167 bitcoins for $190.5M in cash - In a regulatory filing, MicroStrategy disclosed that during the period between February 15 and April 4, MicroStrategy, through its wholly-owned subsidiary, acquired approximately 4,167 bitcoins for approximately $190.5M in cash, at an average price of approximately $45,714 per bitcoin, inclusive of fees and expenses. As of April 4, MicroStrategy, together with its subsidiaries, held an aggregate of approximately 129,218 bitcoins, which were acquired at an aggregate purchase price of approximately $3.97B and an average purchase price of approximately $30,700 per bitcoin, inclusive of fees and expenses, with MacroStrategy holding approximately 115,110 of these bitcoins, the company stated.

09:21 EDT Synaptogenix announces publication of peer-reviewed article on Bryostatin - Synaptogenix announced the recent publication of a collaborative peer-reviewed article in Frontiers in Aging Neuroscience. The research, led by Dr. Jarin Hongpaisan of the Kimmel Medical College of Thomas Jefferson University, resulted from a long-standing collaboration with Dr. Daniel Alkon, President and Chief Science Officer of Synaptogenix. Alkon commented, "This publication of Bryostatin's new efficacy in a well-respected journal is exciting. Through samples accessed via our collaboration with the NIH-sponsored Harvard brain bank, we were able to identify evidence that brain samples from Alzheimer's patients had deficiencies in vascular micro-vessels. We identified the same deficiency in AD mice and subsequently treated them with Bryostatin. The treatment not only stabilized the decline, but importantly led to an increase in new micro-vessels. This exciting new data showing a quantitative increase in blood vessels in mice offers encouragement for our Phase 2b clinical trial of Bryostatin-1 in AD patients, which is currently underway."

09:20 EDT CEA Industries' Surna signs contract for new addition to product portfolio - CEA Industries subsidiary, Surna Cultivation Technologies announced it has converted another new product in its portfolio to an order, in under thirty days. The contract was with an existing customer that came to Surna to retrofit their existing grow with air sterilization equipment and had previously contracted with Surna for their engineering, 4-pipe chilled water climate control, and Sentry IQ controls system. The Air Sniper units keeps the air and plants clear of damaging contaminants. Troy Rippe, Surna's Vice President of Product Development, stated, "This is also a great example of how some of the new products being added to Surna's offerings isn't just for new facilities, but also for existing cultivators that can capitalize on this kind of add-on equipment. As Surna continues to expand its product portfolio, we will offer solutions for more and more cultivators, including those already in operation."

09:19 EDT Cue is now an available point-of-care solution for BioReference's customers - Cue Health (HLTH) and BioReference Laboratories, an OPKO Health (OPK) company announced that Cue is now an available point-of-care solution for BioReference's clinical customers, including for healthcare providers and point-of-care clinics in the U.S. Cue's innovative Cue Clinic provider dashboard will be the keystone product offered through BioReference. Cue Clinic will provide healthcare providers with a full suite of integrated digital patient care services, including test results from the Cue Health Monitoring System, virtual care capabilities, scheduling, e-prescriptions, reporting, and more.

09:18 EDT Cyren announces competitive replacement program for anti-virus engine - Cyren announced a competitive replacement program for organizations that need a different provider of malware detection capabilities. The new program includes technical resources, flexible integration timelines, and mutually beneficial business terms to accommodate planned and unexpected projects to replace alternative anti-virus and anti-malware engines.

09:17 EDT Qualigen resumes worldwide distribution, commercial control of FastPack - Qualigen Therapeutics announces the official resumption as of April 1, 2022 of worldwide distribution and commercial control of FastPack from previous marketing partner Sekisui Diagnostics. Michael Poirier, Qualigen's Chairman and CEO, commented, "We are excited to resume all sales and marketing control of our FastPack business. We remain grateful to Sekisui for the successful partnership since 2016, and now welcome the opportunity to realize the full benefit of our end-to-end efforts, which will provide Qualigen 100% of the revenue from FastPack(R) sales as we aim to improve the health of substantially more patients. We have been steadfastly preparing for increased demand that could result in increased revenue, along with the increase in per-unit profitability for our diagnostics business, a key pillar of our diversified life sciences strategy."

09:16 EDT NextPlay Technologies selected by DIG to offer fiat payment, banking services - NextPlay Technologies has entered into a preliminary agreement with Decentralised Investment Group, DIG, a leading global blockchain technology company, to develop and operate an exclusive fiat payment platform for DIG customers. Upon execution of a definitive agreement, NextBank International, NextPlay's global banking unit, would provide DIG customers with access to its Fintech platform, which would enable these customers to purchase and monetize DIG assets. This would initially include in-game assets from Realms of Ethernity, RoE. Realms of Ethernity is a blockchain World of Warcraft-inspired virtual world filled with hundreds play-to-earn games where developers and players can build, own and monetize their gaming experience offered by DIG's subsidiary, XYZZY. The payment platform would allow customers to purchase and sell in-game assets using fiat currencies. NextBank would also offer bank accounts to DIG customers for their fiat deposits, subject to the customer passing NextBank compliance verification.

09:15 EDT Tivity Health trading resumes

09:12 EDT WSFS Bank appoints Kumar as SVP, Head of Corporate Finance - WSFS Bank, the primary subsidiary of WSFS Financial, announced Shilpa Kumar as Senior Vice President, SVP, Head of Corporate Finance, reporting to Dominic Canuso, CFA, Executive Vice President and Chief Financial Officer. In her new role, Kumar will lead consolidated business planning and analysis, investor relations, business unit profitability, investment decisioning, and the financial aspects of corporate development. Kumar has nearly 20 years of experience in the banking and financial services industry. Most recently, she served as Head of Financial Planning and Analysis at Citadel Credit Union.

09:11 EDT Dave & Buster's to offer its Eat & Play Combo - Dave & Busters announced its Eat & Play Combo returned on Monday, March 28th to more than 140 locations nationwide. With the Eat & Play Combo, guests get a Game Card and an entree for only $19.99. Back for a limited time only, March 28 to May 1, guests can enjoy their choice of one of seven chef-crafted entrees plus a $10 Power Card for $19.99.

09:10 EDT LPL Financial releases 2022 sustainability report - LPL Financial Holdings announced the release of its 2022 Sustainability Report detailing the firm's progress toward its environmental, social and governance goals. Guided by the company's continued ESG vision to take care of its advisors and their clients by operating responsibly and ethically, the report reflects the firm's progress in key focus areas, including diversity, equity and inclusion; responsible sourcing; sustainable investing; environmental stewardship; and community support. Highlights from this year's report include: Growth in LPL sustainable investing; client assets in investments reflective of ESG criteria doubled to $770.6 million, compared to 2020 Inaugural appearance among Newsweek's 2021 America's Most Responsible Companies ranking; Ranked by Just Capital among the Top 100 U.S. Companies Supporting Healthy Families and Communities; The LPL Financial Foundation, which focuses on advancing the economic well-being of underserved populations, formed two new charitable partnerships with The American College of Financial Services and LISC; Of the 2021 class of LPL interns, 75 percent identified as a woman or a person of color; Completed first diverse supplier assessment and began exploring new opportunities to partner with diverse suppliers, including women-, minority-, veteran-, and disabled- owned businesses.

09:08 EDT data.world announces $50M Series C funding led by Goldman Sachs Asset Management - data.world announced a $50M Series C financing led by the Growth Equity business within Goldman Sachs Asset Management. Additional investors include Prologis Ventures, Shasta Ventures, Vopak Ventures, Sandbox Insurtech Ventures, Paul Albright, Rick Braddock, Zachary Karabell, Dave Liu, and Scott Stephenson. Total fundraising now stands at $132.3M. The company said, "data.world's cloud-native SaaS data catalog combines an intuitive user experience and knowledge-graph foundation to deliver powerful data discovery, agile data governance, and actionable insights. The company has a strong customer base across multiple verticals including banking, insurance, high-tech, healthcare, and the public sector. Customers include Penguin Random House UK, Prologis, Verisk Analytics, WPP, the Associated Press, and Vopak. One of the few Certified B corporations in the data and analytics space and home to the world's largest collaborative open data community, data.world is mission-driven to help organizations transform raw data into knowledge that everyone can use. The additional capital will accelerate data.world's global expansion, talent acquisition, and product innovation to meet the growing market demand for its next-generation data catalog. As part of the transaction, Mike Reilly, a vice president in the Growth Equity business within Goldman Sachs, has joined the data.world Board of Directors."

09:06 EDT Lawson Products CEO Michael DeCata to retire, Cesar Lanuza to succeed - Lawson Products announced the appointment of Cesar Lanuza as president and CEO of Lawson's operating company, and the retirement of president and CEO, Michael DeCata, effective April 4, as part of an ongoing succession plan. DeCata will transition his role through May 1 when he will also retire from his remaining positions, including as a member of Lawson's board of directors and will then assume a role providing advisory services to Lawson's board as part of a four-year agreement. Lanuza brings a combined 30 years of global experience, who most recently served as CEO and director at Jon-Don.

09:06 EDT Valvoline renews multi-year partnership agreement with Toronto Blue Jays - Valvoline announced a renewal of their partnership agreement between Valvoline Canada and the Toronto Blue Jays. After teaming up for the first time in 2021, the new multi-year contract extends the relationship, making Valvoline Canada an Official Partner while providing national marketing rights throughout the 2022 season and beyond. Valvoline will be prominently displayed behind home plate during all regular season home games. New for 2022, Valvoline LED signage will be featured in stadium during select home games. Additionally, the partnership will be supported via an out of home advertising campaign, through digital and social channels, plus print ads in the Toronto Blue Jays game day program and yearbook.

09:05 EDT CleanSpark announces 318 bitcoin produced in March - CleanSpark released its unaudited bitcoin production and operations update for the calendar year-to-date ending March 31, 2022. Bitcoin Production & Operations Update: March monthly production: 318; Calendar year-to-date production ending March 31: 898; Total BTC holdings as of March 31: 420; Total BTC converted for operations and growth in March: 391; Currently deployed fleet of over 23,000 latest-generation bitcoin miners with a total hashrate of 2.3 EH/s . The Company fully funded growth and operations through the sale of 420 bitcoins in March 2022 at an average of approximately $42,294 per BTC. Sales of BTC equated to proceeds of approximately $17.6 million, most of which was used for growth capital expenditures at the company's Norcross facility. March daily BTC production reached a high of 10.57.

09:05 EDT Skillful Craftsman announces cooperation agreement with Newlink - Skillful Craftsman Education Technology announced that Shenzhen Qianhai Jisen Information Technology, the wholly-owned subsidiary of Wuxi Kingway Technology, has entered into a strategic cooperation agreement with Newlink Technology, an IT solutions provider, to jointly develop robotic process automation, or RPA, technology and a new vocational training environment based on AI and digital twin technology. Pursuant to the Agreement, both parties agree to jointly develop the RPA technology. Newlink agrees to provide the fundamental technologies, and Jisen agrees to conduct research on the business demand of targeted companies and provide research and development solutions based on its research. Both parties also agree to jointly develop digital twin technology based vocational training environment, to provide training for employees at financial institutions and college students. Jisen agrees to provide Newlink's customers with technical supports of virtual reality and the application of AI scenarios. As part of the Agreement, both parties agree to collaboratively work on industry expansion and increase each other's business presence in both respective specialized industries. Both parties will also conduct in-depth cooperation in marketing and sales, including granting rights of distribution, project implementation, outsourcing, and operation and maintenance execution to the other party.

09:04 EDT Udemy launches in South Korea, expanding global footprint - Udemy announced its partnership with Korean AI education company, Woongjin ThinkBig. This partnership further expands the company's global footprint, bringing Udemy and its corporate learning solution, Udemy Business, to the Korean market. "Korea is an important market for Udemy given the focus on education and continuous learning in the country," said Gregg Coccari, CEO of Udemy. "We are excited to partner with Woongjin ThinkBig to help bring Udemy to more learners and instructors in Korea, and to help Korean organizations meet their learning goals and achieve better business outcomes."

09:03 EDT Verisk Analytics announces agreements with CSLN, OCSE - Life insurers will be able to help streamline matching of claim settlements with outstanding child support obligations under agreements Verisk announced with the Child Support Lien Network and the federal Office of Child Support Enforcement. The collaboration expands automated child support matching available for property/casualty insurers to the life industry. More than $114 billion of child support payments are past due in the United States, according to OCSE, reflecting U.S. Census data that counts more than 12.9 million custodial parents-half of whom have some form of legal or informal child support in place. A growing number of states require insurers to match settlements to claimants who owe past-due child support, so these outstanding financial obligations can be met when claims are paid.

09:01 EDT Nucor acquires Elite Storage Solutions for $75M - Nucor announced that it has acquired steel racking manufacturer Elite Storage Solutions for $75M. This acquisition expands Nucor's steel racking capabilities and builds on the company's acquisition of Hannibal Industries last year. Elite Storage Solutions employs 180 full-time teammates at locations in Monroe, Georgia, and Chandler, Arizona.

08:54 EDT Tivity Health to be acquired by Stone Point Capital for $32.50 per share in cash

08:52 EDT Nano-X Imaging opens new semiconductor chip fabrication plant in South Korea - Nano-X Imaging announced that it has opened its new semiconductor chip fabrication plant in South Korea. The facility is operational, opened on schedule, and will be the main production site of Nanox micro-electro-mechanical systems, or MEMs, known as Nanox.Source, a chip that produces the digital X-ray source for the company's Nanox.Arc system, a 3D medical imaging system. Nanox expects to get to scale for production by mid-year 2022. Additionally, Nanox has been building its production line capabilities and establishing an operational assembly line at its Israeli facility to enable the expected ramp up in production and preparation for shipments of the Nanox.Arc system. The new facility is an advanced fabrication plant, dedicated to the production of MEMs. Strategically located next to the world's largest semiconductor cluster in Yongin, South Korea, the Nanox facility spans 12,000 square meters, including a 1,200-square-meter MEMs clean room.

08:49 EDT Omniq closes acquisition of additional 23% of Dangot Computers - OMNIQ has acquired additional 23% of Dangot Computers Ltd making it a fully owned subsidiary, effective April 1st , 2022. The Company has paid $3,518,000 in consideration for the exercise of which $3.1M was financed from a combination of short and long term loans. The company said, "Dangot is a profitable, prominent player in the field of automation and frictionless equipment. Its systems have gained an excellent reputation and significant market share in the demanding Israeli market, providing innovative solutions globally for multiple vertical markets including healthcare, retail, restaurants, and warehouse automation." Dangot's stand-alone revenue for fiscal year 2021 was approximately $40 Million with approximately $2M in profit before taxes.

08:43 EDT Solitario announces assay results for surface grab samples from Sunrise - Solitario Zinc is pleased to report that it has received new assay results for select surface grab samples from a new area called Sunrise, located on the Company's Golden Crest property in South Dakota. The three highest-grade rock grab samples contained 20.1, 17.6 and 7.9 grams per tonne gold. In addition, highly anomalous sample results were received for the Treasure Vault and Log Jam prospects, further confirming the potential of these two areas. Sampling results from the Sunrise area suggests a zone of anomalous to high-grade gold mineralization that extends for at least 900 meters in a northwest-southeast trending zone that is up to 200 meters wide. Additional sampling is planned at Sunrise to better define this zone. Chris Herald, President and CEO of Solitario, commented: "We are thrilled to make another discovery of greater than 10 grams per tonne gold at surface right on the heels of our Downpour announcement. Assays like these are rare, and even more so in a virtually unexplored area located in the shadow of a Super Giant gold deposit. We believe we are more at the beginning of our discovery process, rather than nearing the end. The 2022 exploration season is nearly upon us, and we expect much more positive news to come." In total, 25 new assay results are reported from five different areas within the Golden Crest property position. Significant assay values from surface grab samples were received for the Treasure Vault and Log Jam prospect areas, as well as single samples from two new prospect areas. These assays, combined with previous results, point to the potential expansion of the surface expression of mineralization at these emerging prospects.

08:40 EDT Jaguar Health appoints Pravin Chaturvedi as CSO, chair of SAB - Jaguar Health has been appointed Chief Scientific Officer, CSO, and Chair of the Scientific Advisory Board, SAB, of Jaguar. Prior to this appointment, Dr. Chaturvedi served as Chair of the company's SAB and Acting CSO of Jaguar and Napo Pharmaceuticals, Jaguar's wholly owned subsidiary. As part of his responsibilities as CSO and Chair of the SAB, Dr. Chaturvedi will also support Napo Therapeutics' efforts to initiate a pivotal clinical trial of crofelemer for short bowel syndrome, SBS.

08:39 EDT Redwire selected by Air Force to compete for task orders on $950M IDIQ contract - Redwire announced it has been selected by the U.S. Air Force to compete for task orders alongside several other companies under an indefinite delivery/indefinite quantity, or IDIQ, contract to support its Advanced Battle Management System, or ABMS. This program is the Air Force's contribution to the Department of Defense's, or DOD, Joint All Domain Command and Control Architecture, or JADC2, which focuses on modernizing DOD decision-making processes for combat operations. The IDIQ has a $950M ceiling, which is shared across all awardees with no guaranteed task orders, for the maturation, demonstration and proliferation of capabilities across platforms and domains, leveraging open systems design, modern software and algorithm development in order to enable JADC2. This contract is part of a multiple award multi-level security effort to provide development and operation of systems as a unified force across all domains in an open architecture family of systems that enables capabilities via multiple integrated platforms.

08:38 EDT Bridgeline Digital provides update after end of its Q2 - Bridgeline Digital provided the following update after the end of its fiscal second quarter, which concluded on March 31, 2022. Bridgeline reported that it closed 33 license sales totaling over $650k in ARR in the second quarter of fiscal year 2022. Bridgeline's cross-sale strategy remains strong, with 9 license sales to its existing customer base on top of 24 newly won customers. "Bridgeline won more customers in this quarter than any quarter in history. These robust bookings will add strong high-margin recurring revenue to our subscription revenue in future quarters," said Ari Kahn, Bridgeline's President and Chief Executive Officer. "Bridgeline's new product launches and strong partnerships have contributed to this quarter's sales and positioned the company for strong sales in future quarters." Bridgeline has added over $100k in ARR this fiscal year to date for the DataBravo product. Nine existing customers purchased Bridgeline's latest products, including the National Notary Association, which selected Hawksearch to deliver more accurate results to their customers. With platform partnerships, Bridgeline currently supports Optimizely customers Crescent Electric and Cleaner's Supply. Bridgeline secured deals with several companies in the distribution industry this quarter.

08:37 EDT ICE reports March ADV up 9% and total open interest up 5% y/y - "In the first quarter of 2022, the war in Ukraine brought both geopolitical risk and supply uncertainty across commodity markets as inflationary pressure underpinned activity in interest rate markets," said Ben Jackson, President of ICE. "Our benchmark futures contracts help to price commodities that millions of people rely on, providing our customers with the risk management tools they need in the midst of a crisis." March highlights include: Total average daily volume ADV up 9% y/y and total open interest OI up 5% y/y TotalEnergy ADV up 4% y/y; OI up 4% y/y ;Brent ADV up 4% y/y.

08:36 EDT Aditx Therapeutics enters revenue sharing agreement with Cellvera - Aditxt has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the company's $14.5M loan, plus interest to Cellvera, formerly AiPharma. The company has signed the agreement as consideration for Aditxt's separate agreement to extend the term of the previously announced loan and forbearance agreements. Cellvera holds exclusive worldwide rights to a spectrum of oral antiviral drug targeting COVID-19 and 11 other infectious diseases. Cellvera is focused on discovering, developing, and commercializing antimicrobial therapies across a broad spectrum of infectious diseases, including COVID-19. Under the terms of the agreement, Aditxt will receive up to 10% of net sales of products and services collected by Cellvera and other loan parties up to a maximum of $30M. Aditxt has agreed to apply approximately the first $14.5M of the revenue share payments it receives from the loan parties as repayment of the loan, plus interest until Cellvera's loan obligations are satisfied. In addition, the loan's security agreements have been enhanced to include all assets of Cellvera. Cellvera and Aditxt have also amended their previously announced share exchange agreement to: modify the financial statements required to be delivered by Cellvera prior to the initial closing, permit the company to amend its Certificate of Incorporation without the consent of Cellvera in order to effect a reverse stock split of the company's common stock, if necessary, in order to maintain its listing on the Nasdaq and make certain other conforming changes related to the forbearance agreement and revenue sharing agreement. Work is proceeding on the first step of the acquisition, for which the due diligence period has been extended. The closings of the transactions contemplated under the share exchange agreement are subject to satisfactory completion of due diligence as well as several other closing conditions, including shareholder approval. There is no assurance that Aditxt's acquisition of Cellvera will be completed.

08:35 EDT Infobird signs cooperation agreement with Taikang Healthcare Holdings - Infobird announced that it signed a cooperation agreement with Taikang Healthcare Industry Investment Holdings. Taikang Healthcare Investment Holdings is a wholly-owned subsidiary of Taikang Insurance Group, specializing in investment and development, asset management and operation services for the medical care and health industry. Taikang Healthcare Investment Holdings has a registered capital of 3B RMB, which is the core platform and carrier for Taikang's large and growing healthcare business. Through this cooperation, Infobird will provide its full suite of digital contact center solutions to assist Taikang Healthcare Investment Holdings telemarketing and customer service department, home care service center and high-quality elderly care community and create an omni-channel intelligent contact solution to comprehensively improve the efficiency and quality of customer service.

08:34 EDT Bit Digital, BitMine Immersion sign LOI for hosting 7,000 mining computers - Bit Digital and BitMine Immersion Technologies announce the signing of a Letter of Intent to establish a hosting relationship beginning with 7,000 current generation ASIC miners. The final agreement is expected to be completed in the coming weeks. The companies expect to primarily utilize the efficiencies of mining Bitcoin in immersion cooled containers, a process by which the servers run fully submerged in a dielectric fluid that efficiently cools the machines and allows for superior machine output and energy efficiency. The companies have agreed in principle to a mutually beneficial revenue split of the mined Bitcoin, and a multi-year term. Bit Digital and BitMine Immersion hope to begin delivery in the coming weeks and months and fill the capacity by the end of August.

08:33 EDT Agenus' announces receipt of $5M milestone payment for AGEN2373 - Agenus announced receipt of a $5M clinical milestone payment for AGEN2373. AGEN2373 is being evaluated in a Phase 1b combination study with botensilimab, in melanoma patients who had relapsed on, or were refractory to, prior anti-PD-1 therapy. "The majority of patients treated with anti-PD-1 progress within a year and are in need of more effective treatment options," said Steven O'Day, MD, Chief Medical Officer of Agenus. "Botensilimab has shown promising activity in a wide range of treatment-resistant cancers, including melanoma. The rationale to combine botensilimab and AGEN2373 is based on preclinical evidence we reported of enhanced tumor control with this approach in a PD-1 resistant melanoma model. This study represents a rationally designed combination strategy to bring novel therapies to cancer patients."

08:32 EDT Allergan announces results from Phase 3 VIRGO trial - Allergan, an AbbVie company, announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY, or pilocarpine HCl ophthalmic solution, 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distance vision at Hour 9 on Day 14. Additional details of this trial will be presented at future medical congresses and will serve as the basis for a supplemental New Drug Application submission for an optional twice-daily administration to the FDA in the Q2. Approved by the FDA in October 2021 for once-daily use, VUITY is the first and only eye drop to treat age-related blurry near vision in adults. In the VIRGO Phase 3 trial, a total of 230 participants aged 40 to 55 years old with presbyopia were randomized in a one-to-one ratio of vehicle to VUITY, receiving two drops in each eye per day for 14 days, with the second drop at Hour 6. The study met its primary endpoint, showing a statistically significant proportion of participants treated with VUITY twice daily gained three lines or more in mesopic, high contrast, binocular Distance Corrected Near Visual Acuity, or DCNVA, with no more than 5-letter loss in low light Corrected Distance Visual Acuity at Day 14, Hour 9 versus the vehicle.

08:32 EDT Twitter to appoint Tesla CEO Elon Musk to board of directors - In a regulatory filing, Twitter disclosed that on April 4, the company entered into a letter agreement with Elon Musk, which provides that the company will appoint Mr. Musk to the company's board of directors to serve as a Class II director with a term expiring at the company's 2024 annual meeting of stockholders. For so long as Mr. Musk is serving on the board and for 90 days thereafter, Mr. Musk will not, either alone or as a member of a group, become the beneficial owner of more than 14.9% of the company's common stock outstanding at such time, including for these purposes economic exposure through derivative securities, swaps, or hedging transactions, the agreement also stipulates, the company disclosed.

08:32 EDT Keurig Dr Pepper announces CFO Ozan Dokmecioglu to become CEO later this year - Keurig Dr Pepper announced a CEO transition plan that leverages the successful partnership between Chairman & CEO Bob Gamgort and CFO Ozan Dokmecioglu to ensure continuity of the company's leadership and strategic direction, while strengthening KDP's focus on deploying its exceptional discretionary free cash flow to create shareholder value. The KDP Board of Directors has appointed Ozan Dokmecioglu, currently CFO & President of International, as the company's next CEO, effective July 29. Dokmecioglu will join the company's Board of Directors at that time. Bob Gamgort, currently Chairman and CEO, has committed to serve as Executive Chairman of KDP for two years. As part of the transition, Gamgort and KDP have entered into an agreement for his role as Executive Chairman, in which Gamgort has committed to remaining a significant investor in KDP, maintaining at least half of his KDP shareholdings during his tenure as Executive Chairman.

08:30 EDT Twitter to appoint Elon Musk as a Class II director

08:29 EDT Micron appoints Mark Murphy as eVP, CFO - Micron Technology (MU) announced that it is appointing Mark Murphy as the company's executive vice president, eVP, and chief financial officer, CFO, effective April 18, 2022. Murphy will report to Mehrotra and oversee Micron's finance organization, including all finance functions, tax, treasury, internal audit and investor relations. He will be responsible for driving capital allocation to optimize revenue growth, profitability and shareholder returns. Murphy will be joining Micron from Qorvo (QRVO), where he has been CFO since 2016. With Murphy's appointment, interim CFO Sumit Sadana will return full time to his role as chief business officer for the company.

08:27 EDT iCAD announces additional patients treated under GLIOX trial - iCAD announced that additional patients have been treated under the international multi-center GLIOX trial and customers globally are continuing to expand use of intraoperative radiation therapy, IORT, for the treatment of multiple tumor types, including brain, rectal, and head and neck cancers using the Xoft Electronic Brachytherapy System. Recently, doctors at Caceres University Hospital in Caceres, Spain have successfully treated multiple cases of recurrent glioblastoma with the Xoft System, which were performed in preparation for the GLIOX trial, as well as brain metastases, recurrent rectal, and head and neck tumors. In parallel, clinicians at the Miguel Servet University Hospital in Zaragoza, Spain, have utilized Xoft IORT in their cancer treatment regimen for sarcomas and brain metastases, as well as more than 700 breast cancers and 200 gynecological cancers to date. "The Xoft System offers the flexibility to treat multiple types of tumors with positive clinical outcomes, along with providing time-savings benefits for both patients and clinicians," said Stacey Stevens, President and CEO of iCAD, Inc. "We are encouraged to see more facilities adding new indications for the Xoft System, as it provides a practical solution that offers the potential to optimize treatment times and reduce side effects, which ultimately enhances patient care." Having now treated multiple patients, researchers expect the GLIOX study will validate results from a prospective two-center comparative study supporting Xoft Brain IORT recently published in Surgical Neurology International. This study evaluated 15 patients with recurrent GBM who were treated with maximal safe resection and Xoft Brain IORT, and 15 patients with recurrent GBM treated with maximal safe resection and other modalities. As of March 2021, when the study was published, patients treated with Xoft Brain IORT lived for up to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 10 months and lived for up to 22.5 months after treatment.

08:26 EDT Oramed receives NAsh patent in Europe - Oramed Pharmaceuticals announced that the European Patent Office has granted the Company the patent titled "Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof." This patent was previously granted to Oramed in the U.S. and is pending in several other major markets. Oramed recently announced 100% enrollment in its Phase 2 trial which is assessing the safety and potential efficacy of its oral insulin ORMD-0801 in type 2 diabetes patients with non-alcoholic steatohepatitis, or NASH. Data from a prior pilot study of ORMD-0801 in this indication showed a reduction in liver fat content.

08:25 EDT Arteris IP says BMW license FlexNoC interconnect IP - Arteris IP (AIP) announced that BMW Group (BMWYY) has licensed FlexNoC interconnect IP and the accompanying FlexNoC Resilience Package IP for use in a chip partially funded by the German Federal Ministry of Education and Research as part of the ZUSE-KI-mobil publicly funded project. The goal of the project is to develop an accelerator chip for high-end deep learning applications that is a leap forward in terms of energy efficiency, reliability, robustness and security, which go far beyond current possibilities. BMW Group is serving as the coordinator and leader of the project.

08:22 EDT Mersana Therapeutics to present preclinical data on XMT-1660, XMT-2056 - Mersana Therapeutics announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research Annual Meeting 2022 to be held in New Orleans, Louisiana from April 8-13, 2022. XMT-1660 is a Dolasynthen ADC targeting B7-H4, a target selectively expressed on tumors in areas of high unmet medical need, including breast, endometrial, ovarian and other cancers. The data show that a single dose of XMT-1660 has anti-tumor activity in both triple-negative breast cancer and estrogen receptor -positive breast cancer xenograph models. Higher B7-H4 expression is associated with greater anti-tumor activity of XMT-1660 in preclinical studies. Mersana expects a Phase 1 clinical trial for XMT-1660 to start in mid-2022. XMT-2056, Mersana's first Immunosynthen STING-agonist ADC, targets a novel epitope of HER2, and is designed to offer a differentiated and complementary therapeutic approach to the treatment of HER2-expressing tumors. The preclinical data presented show that XMT-2056 demonstrates robust anti-tumor activity as a monotherapy in both HER2-high and HER2-low expressing models. XMT-2056's complementary mechanism of action results in increased efficacy in combination with trastuzumab, pertuzumab, anti-PD-1, or trastuzumab deruxtecan in preclinical studies. Mersana expects to initiate a Phase 1 clinical trial of XMT-2056 in mid-2022. Immunosynthen is Mersana's immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Data show that anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in an antigen binding-dependent manner in both tumor-resident immune cells and in tumor cells. In addition to delivery to the tumor cell via antigen binding and internalization, data from multiple models demonstrate Fcgamma-R1 is the major receptor that mediates delivery to a specific population of myeloid cells resident in primary human tumors, eliciting potent anti-tumor responses in preclinical studies.

08:20 EDT Teledyne announces release of Camera Link HS line scan camera - Teledyne DALSA is pleased to announce the release of its multispectral Camera Link HS line scan camera-a new model of the award-winning Linea product line. This latest high resolution line scan camera provides spectrally independent RGB and NIR outputs making it uniquely capable of handling some of the most challenging inspection applications by detecting defects both on and under the surface of a wide variety of materials, components, and products.

08:20 EDT Ree Automotive appoints Josh Tech as Chief Operations Officer - REE Automotive (REE) announced the appointment of operations and manufacturing executive Josh Tech as the company's chief operations officer, COO. Tech joins REE after serving on Tesla's (TSLA) Operations Leadership Team as Head of the New Product/Manufacturing Introduction group. As REE's COO, Tech will be based in the U.S. and lead all aspects of REE's operations, manufacturing, and global expansion management.

08:19 EDT Taurus, Kayne Anderson Real Estate form joint ventrue to acquire property - Taurus Investment Holdings and Kayne Anderson Real Estate, the real estate private equity arm of Kayne Anderson Capital Advisors, L.P., announced today the formation of a joint venture to acquire Halstead Framingham, a 1974 vintage, 1,020-unit apartment community located in Framingham, Massachusetts. Following the transaction, the property will be renamed The Green at 9 & 90. The joint venture plans to commit significant capital to transition The Green to a low-carbon, energy-efficient multifamily community. In addition to the sustainability-focused retrofit, the joint venture plans to implement a range of tenant-driven social activations such as rent reporting to help tenants build credit through on-time rent payments and prioritization of partnering with diverse-owned businesses vendors.

08:16 EDT Sandstorm Gold renews its normal course issuer bid - Sandstorm Gold announces that the Company's normal course issuer bid, or NCIB, is being renewed after the existing NCIB expires on April 6. The current NCIB provides Sandstorm with the option to purchase up to 19.1M of the Company's common shares from time to time when Sandstorm's management believes that the Common Shares are undervalued by the market. Under the renewed NCIB, Sandstorm may purchase up to 18.9M of its Common Shares, representing approximately 10% of the Company's issued and outstanding Common Shares of 192,224,215 as of March 31 less those Common Shares held by the Company's directors and senior officers. The new NCIB also provides Sandstorm with the option to purchase its Common Shares from time to time when Sandstorm's management believes that the Common Shares are undervalued by the market. The Toronto Stock Exchange has accepted the Company's notice that it intends to proceed with a NCIB in accordance with TSX rules. Purchases under the renewed NCIB may commence on April 7 and will terminate on the earlier of April 6, 2023, the date that Sandstorm completes its purchases pursuant to the NCIB as filed with the TSX, or the date of notice by Sandstorm of termination of the NCIB. All purchases under the NCIB will be executed on the open market through the facilities of the TSX or alternative Canadian trading platforms and through the facilities of the NYSE or alternative trading platforms in the United States of America. Purchases will be made at the market price of the Common Shares at the time of acquisition and may be funded by Sandstorm's working capital. Any Common Shares acquired by the Company under the NCIB will be cancelled. Sandstorm's average daily trading volume on the TSX during the last six calendar months was 270,139 Common Shares. Under the rules of the TSX, subject to the Company's ability to make block purchases, daily purchases on the TSX under the NCIB will not exceed 67,534 Common Shares, which represents 25% of the average daily trading volume on the TSX during the last six calendar months. The maximum number of Common Shares which can be purchased per day on the NYSE will be 25% of the average daily trading volume for the four calendar weeks preceding the date of purchase, subject to certain exceptions for block purchases. The actual number of Common Shares that may be purchased and the timing of such purchases will be determined by the Company. Decisions regarding purchases will be based on market conditions, share price, best use of available cash, and other factors. In the last twelve months, the Company has purchased 4,651,049 Common Shares pursuant to its NCIB at a weighted average price of approximately C$7.95 per common share on the TSX and alternates and approximately US$6.19 per common share on the NYSE and alternates.

08:15 EDT MiMedx to present health economics clinical data for EPIFIX - MiMedx Group announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care Spring on April 6-10 in Phoenix, Arizona. The session will highlight data demonstrating beneficial outcomes in patients receiving EPIFIX in the treatment of chronic wounds, specifically focusing on the observed benefit in the reduction of amputations in lower extremity diabetic ulcers, and a subsequent cost-effectiveness analysis when applying EPIFIX by defined parameters for use. Co-authors of the study, Dr. David G. Armstrong and Dr. William H. Tettelbach, will present the data and answer questions at the event. Additionally, the Company will present three accepted poster abstracts on its PURION(R) processed allografts, two related to the treatment of LEDU, and one, a preclinical study highlighting the retained placental properties that may modulate fibrotic mechanisms in conditions characterized by excessive fibrosis or scarring.

08:14 EDT CommScope partners with Orange Belgium to deploy new set tops - CommScope (COMM) has partnered with Orange Belgium (MBISF) to provide its subscribers with the latest generation of set tops powered by the Android TV operating system designed to provide both live television and premium streaming services.

08:12 EDT Qorvo announces CFO Murphy departing to join Micron as its CFO - Qorvo (QRVO) announced that Chief Financial Officer, CFO, Mark Murphy is leaving the Company effective April 18, 2022. Murphy was appointed Qorvo's CFO in June 2016 and is departing to join Micron Technology (MU) as its CFO. Qorvo has initiated a comprehensive search for a new CFO. Qorvo's Vice President of Treasury, Grant Brown, has been named interim CFO through the transition period. The company's guidance for its fiscal 2022 fourth quarter, provided February 2, remains unchanged.

08:11 EDT electroCore enters exclusive license agreement with Teijin for Japan - electroCore announced it has entered into an agreement with Teijin Limited to license certain exclusive rights to its non-invasive vagus nerve stimulation technology for commercialization in Japan for a range of primary headache disorders. Under the agreement, the Company will receive a non-refundable, upfront payment for the licenses and rights granted to Teijin. The financial terms contain milestone payments, payable upon the decision by Teijin to commercialize the licensed product for specific indications. The Company also will receive an annual license fee commencing on the first anniversary of the agreement and payable annually until the first commercial sale on any approved indication. Upon favorable regulatory and payor coverage decisions in Japan, the parties will enter into an exclusive commercial supply agreement for gammaCore nVNS. The agreement contains customary terms and conditions, including renewal and termination provisions, as well as minimum purchase commitments once a commercial supply agreement is in place. Furthermore, Teijin is responsible for all costs associated with regulatory approval by the Pharmaceuticals and Medical Devices Agency, the Japanese FDA equivalent. As part of the agreement, Teijin will have the right of first negotiation for a license to additional indications in Japan.

08:09 EDT Enservco president, CFO Marjorie Hargrave to depart April 22 - Enservco Corporation (ENSV) announced that Mark Patterson has joined the Company as Senior Vice President. Patterson is the former Board Member and CFO of Express-1 Expedited Solutions, which later changed its name to XPO Logistics (XPO). "We are very pleased to add Mark to our senior management team. He is a highly accomplished executive who has produced excellent results at every company he has been associated with throughout his career," said Rich Murphy, Executive Chairman of Enservco. "We look forward to benefitting from his energy, skill set and experience as we advance our business strategy." Murphy added, "I would also like to thank Marjorie Hargrave for her service to the Company over the past several years. She joined Enservco in 2019 to lead a financial and organizational turnaround as the industry was entering a difficult phase. During her tenure, she was instrumental in reducing operating and overhead expenses and achieved substantial debt reduction and refinancing that strengthened our balance sheet and allowed the Company to weather the downturn. With the successful completion of this process, Marjorie will move on to other opportunities, and we wish her well in her future endeavors. We expect to move quickly to bring on board a new Chief Financial Officer."

08:08 EDT Chinook, IgA Nephropathy Foundation, Komodo Health announce collaboration - Chinook Therapeutics announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A, IgA, nephropathy and engage key medical providers at nephrology practices across the U.S. The collaboration will drive strategic, targeted medical outreach to nephrology care providers to better address the unmet patient need for this rare kidney disease. The initiative also raises awareness about the IgA nephropathy disease burden and ensures patients have access to optimal support and treatment options earlier in their journey. To better support early diagnosis and potentially slow disease progression, this effort will apply insights from Komodo's Aperture software to drive strategic outreach and education to healthcare providers who are likely to encounter patients with IgA nephropathy. Komodo's technology tracks disease burden trends using de-identified, real-world healthcare data for more than 330 million patients in the U.S. "Through our collaborative efforts with the IgA Nephropathy Foundation as well as our work at Chinook developing atrasentan and BION-1301 for IgA nephropathy, we have learned that the patient journey can be daunting and isolating. Managing this condition is not only about the physical symptoms and signs that kidney function may be declining, but also about coping with the challenges, uncertainty and emotions that come with living with IgA nephropathy," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Our collaboration with the IgA Nephropathy Foundation and Komodo Health aims to address these obstacles, arming the patient and provider communities with important tools and connections to improve the diagnostic and treatment journey."

08:07 EDT Koppers completes sale of facility in Sweetwater to Culpeper - Koppers Holdings and Koppers Utility and Industrial Products, a wholly owned subsidiary of Koppers Holdings, announced the completion of the sale of its utility pole treating facility in Sweetwater, Tennessee, to affiliates of Culpeper Wood Preservers. As part of Koppers previously announced strategy to optimize its network of operations, the company has transferred its assets at the Sweetwater facility to Culpeper in exchange for an undisclosed sum. Employees at the site have been given an opportunity to remain with Culpeper.

08:06 EDT Bragg Gaming launches in Ontario with 888casino - Bragg Gaming announced that it launched its content distribution agreement with 888casino in Ontario on the first day of the regulated market opening pursuant to its supplier license from the Alcohol and Gaming Commission of Ontario, or AGCO. The agreement, representing the first of several with iGaming operators in Ontario, includes games from Bragg's exclusive portfolio, such as Egyptian Magic, the recent debut game from its in-house studio Atomic Slot Lab, and others picked specifically for the newly-regulated Ontario iGaming market which opened on April 4.

08:05 EDT Aldeyra completes enrollment in TRANQUILITY-2 Trial - Aldeyra announced completion of enrollment in the Phase 3 TRANQUILITY-2 Trial of 0.25% reproxalap ophthalmic solution in patients with dry eye disease.

08:04 EDT Sono Motors to produce Sion solar EV at Valmet Automotive - Sono Motors and Valmet Automotive announced the signing of a binding term sheet, specifying all substantial parameters regarding the collaboration and the production of the Sion solar electric vehicle. The Finnish contract manufacturer will produce the Sion at its plant in Uusikaupunki. Valmet Automotive will provide the capacity to produce more than 257,000 vehicles over a seven-year period. Valmet Automotive started car manufacturing in 1968 as a joint venture with Saab. Since then, the company built more than 1.7 million cars as a contract manufacturer for some of the world's leading OEMs. General price increases, the switch to Valmet Automotive and the development of new production lines will lead to increased funding needs of at least EUR 275 million by the start of production in the second half of 2023. The Valmet Automotive facilities in Uusikaupunki allow for the production of a low four-digit volume in 2023, which will be followed by a ramp-up period. After this period, which will likely take a few months, the partners aim to produce approximately 43,000 Sion a year, using one hundred percent renewable energy. Sono Motors currently expects that all production-related greenhouse gas emissions that cannot be avoided along its supply chain, or during the production process of the vehicles, will be fully offset through relevant measures. Valmet Automotive is one of the world's most sustainable contract manufacturers and is certified as climate neutral as of 1 January 2022. As of 31 March 2022, the Sion has over 17,000 direct consumer reservations with an average down payment of EUR 2,390 net. Currently priced at EUR 23,950 net, the company is planning to increase the car's estimated net price before taxes and subsidies to EUR 25,126 when the reservation number has reached 18,500. Sono Motors is thereby reacting to the latest increase in manufacturing costs, due to higher prices for production facilities and supplier components as well as raw materials, energy, and logistics, whilst keeping current promised net reservation prices fixed. Sono Motors is currently building a fleet of series-validation vehicles in Germany closer to the company's HQ, ushering in the Sion's testing program. The outer shell of this family-friendly car will consist of 456 seamlessly integrated solar half-cells and will enable self-sufficiency on short journeys. The energy generated by the solar cells will extend the estimated 305 km range of the Sion's 54 kWh LFP battery by an average of 112 km per week. Commuters in metropolitan areas will have to charge their Sion up to four times less than conventional electric cars of the same vehicle class with a similar battery size. Bidirectional charging technology complements the car's solar integration and is designed to turn the Sion into a sustainable power plant on wheels that will be able to power electronic devices, the home or other electric cars with an output of up to 11 kW.

08:03 EDT Southwest Gas calls letter from Carl Icahn 'false and misleading' - Southwest Gas Holdings commented on an open letter to Southwest Gas stockholders published by Carl Icahn on April 4 that the company said "included a number of false and misleading assertions with respect to the company's recent successful public offering of common stock to fund the equity portion of the MountainWest financing." Southwest stated in part: "After thoroughly considering all of the available options, the Southwest Gas Board of Directors executed the equity offering - which was distributed to a diverse set of purchasers and enabled the Company to raise new equity capital in significantly smaller amounts and at a better price than initially projected - to maximize value for all Southwest Gas stockholders. In his April 4th letter, Mr. Icahn selectively quoted a letter sent on behalf of the Company to the Court of Chancery in connection with litigation brought against the Company by Mr. Icahn. Mr. Icahn then falsely accused the Company of 'playing games' with the record date for the meeting in light of the successful equity financing. That is blatantly untrue. The Board proceeded with the equity offering with full knowledge that the purchasers of the newly issued shares would not be able to vote at the annual meeting because the record date already passed... Mr. Icahn also failed to mention it would be illegal for Mr. Icahn to buy shares of SWX in a financing in light of his pending tender offer. The Company will not comment on every false or misleading statement by Mr. Icahn, but the scope of yesterday's misstatements were particularly egregious."

08:02 EDT Bit Digital and BitMine Immersion Technologies sign letter of intent - Bit Digital and BitMine Immersion Technologies announce the signing of a Letter of Intent to establish a hosting relationship beginning with 7,000 current generation ASIC miners. The final agreement is expected to be completed in the coming weeks. The companies expect to primarily utilize the efficiencies of mining Bitcoin in immersion cooled containers, a process by which the servers run fully submerged in a dielectric fluid that efficiently cools the machines and allows for superior machine output and energy efficiency. The companies have agreed in principle to a mutually beneficial revenue split of the mined Bitcoin, and a multi-year term.

07:43 EDT General Motors, Honda expanding relationship to affordable electric vehicles - General Motors (GM) and Honda (HMC) announced plans to expand the two companies' relationship by codeveloping a series of affordable electric vehicles based on a new global architecture using next-generation Ultium battery technology. "The companies are working together to enable global production of millions of EVs starting in 2027, including compact crossover vehicles, leveraging the two companies' technology, design and sourcing strategies. The companies will also work toward standardizing equipment and processes to achieve world-class quality, higher throughput and greater affordability. The compact crossover segment is the largest in the world, with annual volumes of more than 13 million vehicles. GM and Honda also will discuss future EV battery technology collaboration opportunities, to further drive down the cost of electrification, improve performance and drive sustainability for future vehicles," they stated. Mary Barra, GM chair and CEO, said: "This is a key step to deliver on our commitment to achieve carbon neutrality in our global products and operations by 2040 and eliminate tailpipe emissions from light duty vehicles in the U.S. by 2035. By working together, we'll put people all over the world into EVs faster than either company could achieve on its own." Doug Parks, GM executive vice president, Global Product Development, Purchasing and Supply Chain, added: "Our plans include a new all-electric product for North America positioned at a price point lower than the upcoming Chevrolet Equinox EV, building on the 2 million units of EV capacity the company plans to install by the end of 2025."

07:38 EDT Tradeweb Markets reports March trading volume of $28.2T, 14% jump in ADV YoY - Tradeweb Markets reported record total trading volume for March 2022 of $28.2tn. Average daily volume ADV for the month was $1.23tn, an increase of 14.% year-over-year YoY. For the first quarter of 2022, total trading volume was a record $73.1tn and ADV was a record $1.17tn, an increase of 10.9% YoY, with preliminary average variable fees per million dollars of volume traded of $2.93.1 In March, Tradeweb reported record ADV in swaps/swaptions = 1-year. For the first quarter of 2022, Tradeweb reported record activity across most product groups, including: U.S. and European government bonds; swaps/swaptions = 1-year; fully electronic U.S. High Grade and fully electronic U.S. High Yield credit; European credit; U.S. and European ETFs; and Repurchase agreements. March Highlights First Quarter 2022 Record Average Daily Volume up 10.9% YoY

07:35 EDT BitNile announces total investment of $127M on bitcoin mining operations - BitNile (NILE) announced that the company has invested a total of $127M on its bitcoin mining operations at its Michigan data center, including $114.7M in the purchase of bitcoin miners from Bitmain Technologies and $12.3M for the purchase of the data center and infrastructure improvements. This is an update to the company's previous press releases dated November 10, 2021 and November 18, 2021, which initially announced the partnership between BitNile and Bitmain. With the recently announced payment in full of $66M in senior secured debt, other than the loans on the company's portfolio of hotels, which are non-recourse to the parent company, the company is virtually debt free. With the company's recent improvement in its financial condition, it anticipates that over time it will invest up to an additional $70M to $80M in bitcoin miners and infrastructure improvements. The company recently issued its monthly operations report for March, indicating that it has more than doubled its miner count to 4,754 S19j Pro Antminers in its possession, which once installed, is expected to generate a combined processing power of approximately 500 petahashes per second, the computational power that is used to mine Bitcoin (BTC). During the month of March 2022, BitNile mined 31.7 Bitcoin. To date, BitNile has mined a total of 132.6 Bitcoin.

07:34 EDT Avicanna expands partnership with Bio-Gate for Pura H&W distribution - Avicanna announced that it has expanded its previously announced R&D collaboration with Bio-Gate AG with a 5-year exclusive distribution agreement for Pura H&W branded CBD derma-cosmetics. Avicanna and Bio-Gate are expanding their existing research collaboration with the commercial distribution of Avicanna's evidence-based derma-cosmetic line Pura H&W into the European Market. The initial focus of the launch is the German-speaking regions of the continent including Germany, Austria and Switzerland, where Bio-Gate has an established distribution network of pharmacies and retail channels. In addition, Bio-Gate has the right to select 3 additional European countries for exclusive distribution within the first 12 months of the agreement.

07:33 EDT First High-School Education receives non-compliance letter from NYSE - First High-School Education Group announced that it has received a letter from the NYSE, dated March 29 notifying the Company that it is below compliance standards due to the Company's total market capitalization and stockholders' equity, the due date for the Company to submit a business plan that demonstrates compliance is June 27 and the applicable cure period for the Company to regain compliance expires on September 29, 2023. Pursuant to applicable NYSE continued listing standards, a company would be considered "below criteria" by the NYSE if its total market capitalization is less than $50M over a 30 trading-day period and its stockholders' equity is less than $50M. Accordingly, the Company is now subject to the procedures as set forth in Sections 801 and 802 of the NYSE Listed Company Manual, and is required to respond within 90 days of the Letter with a business plan that demonstrates compliance with the continued listing standard within 18 months of receipt of the Letter. The business plan will be reviewed for final disposition by the Listings Operations Committee of the NYSE. To address this issue, the Company intends to comply with the applicable procedures and is still considering its options to regain compliance.

07:32 EDT Destination XL enters three-year extension with Harvey Kanter as president, CEO - Destination XL Group announced that its Board of Directors has extended Harvey Kanter's role as the Company's President and CEO. Mr. Kanter has served as the Company's President & CEO and been a member of its Board since April 1, 2019.

07:31 EDT MindMed names Francois Lilienthal, MD as Chief Commercial Officer - Mind Medicine announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer. With more than two decades of global biopharmaceutical experience and after serving as a consultant for MindMed over the past six months, Dr. Lilienthal will step into this role to support the advancement of the company's clinical development programs.

07:23 EDT Meta Materials receives $2.2M additional central bank purchase orders - Meta Materials announced that it has been awarded $2.2M in additional purchase orders under the development contract between its wholly owned subsidiary, Nanotech Security and a confidential central bank. The new orders include approximately $1M for development services and approximately $1.2M for sample product. On October 1, 2021, just ahead of its merger with META, Nanotech announced that it had renewed its frame agreement to continue development of a unique security feature for its confidential G10 central bank customer. The frame agreement has a maximum value of $41.5 million over a period of up to five years. For fiscal year 2022, the awarded purchase orders under the contract have now increased from approximately $7 million to $9.2 million. "We are proud to receive additional orders from this important customer, reflecting the significant progress we are making developing secure and memorable nano-optic authentication features for potential future banknotes," said George Palikaras, President and CEO.

07:20 EDT Aleafia Health implementing $6.7M in annualized cost savings in 2022 - Aleafia Health is pleased to provide a corporate update on its ongoing cost containment initiatives. Additional cost efficiencies identified represent a further $4.4 million in annualized cost savings to be completed in this quarter and will drive further operational efficiencies, enhance operating leverage, and accelerate the pathway to Adjusted EBITDA breakeven profitability expected to occur in the second half of 2022. The Company also reaffirmed its guidance that it expects to achieve $53.0 to $63.0 million in net revenue in the current fiscal year. "Aleafia Health continues to deliver on its forecast and strategy, experiencing record growth in sales, capturing additional adult-use cannabis market share, and now achieving important efficiencies and additional cost reductions," said Aleafia Health CEO Tricia Symmes. "These organizational realignments helped create a leaner, more nimble workforce optimized to accelerate revenue velocity and maximize margin. It's just the beginning of creating a new Company whose products are focused on the highest revenue generating branded dried flower, pre-roll, and vape product categories as consumers continue to express strong interest in our Sunday Market House of Brands adult-use cannabis products. In 2021, the Company launched a transformational organizational change that successfully identified and put into effect numerous cost efficiencies," said Aleafia Health CFO Matt Sale. "In the quarter ending December 31, 2021, the Company reported reducing its adjusted Selling, General and Administrative expenses by 37% to $7.1 million, from $11.2 million in the period ending December 31, 2020. Management continues to build on that momentum with aggressive cost containment. In the quarter ended March 31, 2022, the Company identified further headcount reductions, operational efficiencies, redundancies, and nonrecurring costs, which together with those already implemented, total $6.7 million on an annualized basis. This demonstrates the Company's unwavering commitment to drive profitability and achieve a sustainable business model. We foresee continued tailwinds to improve our margin profile and drive towards achieving our target of break-even Adjusted EBITDA profitability later this year." In the Company's fast-growing medical business, there was also an integration initiative that identified $1.25 million in annual cost efficiencies through operational process efficiency gains and organizational realignment. These cost savings are reflected in the projected $4.4 million in annualized cost savings. "At the 160,000 sq. ft. Grimsby, Ontario hybrid greenhouse, the Company drove operational efficiencies and remapped its processes to allow its cultivation organization to meet our anticipated growing throughput," said Sale. "We also assessed procurement practices, resulting in a consolidation of certain vendors leading to cost efficiencies. Our cost structure is highly scalable and with international purchase orders in-hand that exceed overseas sales in the second half of 2021. Most recently in March 2022, we made yet another shipment of product to the German market and continue to see robust demand for our products through the remainder of this year," said Sale.

07:19 EDT BioCryst reports board granted 19 newly-hired employees stock options - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 19 newly-hired employees stock options to purchase an aggregate of 124,800 shares, and restricted stock units, RSUs, covering an aggregate of 47,400 shares, of BioCryst common stock. The options and RSUs were granted as of March 31, 2022 as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $16.26 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term.

07:17 EDT GURU Organic, GURU Lite available in 500 ml format across Quebec - GURU Organic Energy is pleased to announce that GURU Original and GURU Lite are now available in a new 500 ml format across all Quebec retailers. The launch of this new format will also be supported by our recently announced, fully integrated marketing campaign, "Made with Plants", which encourages consumers to enjoy the full range of GURU energy drinks.

07:15 EDT Xos delivers 15 fully-electric stepvans to FedEx Ground Operators - Xos (XOS) announced the delivery of 15 of its battery-electric stepvans to five different FedEx (FDX) Ground Operators in Southern California during the month of March. FedEx Ground Operators work as FedEx Corporation independent service providers, ISPs. The ISPs ordered these 15 stepvans in 2021 for 2022 delivery. The orders were previously reported by Xos. "We are pleased to continue delivering vehicles to FedEx Ground Operators and supporting them in meeting their sustainability goals and reducing total cost of ownership," said Jose Castaneda, Vice President of Business Development for Xos. "This is the first of our 2022 deliveries to FedEx Ground Operators and we are excited to continue rolling out our products to this leading, nationwide fleet."

07:13 EDT Bioventus announces inducement equity to SVP, CFO Mark Singleton - Bioventus announced the issuance on April 4, 2022 of previously disclosed inducement equity awards to Mark Singleton in connection with this appointment as Senior Vice President, Chief Financial Officer, and Principle Accounting Officer of the Company. The awards consist of 74,500 restricted share units and options to purchase 223,200 shares of the Company's Class A common stock. Both awards will vest in four equal installments on the first four anniversaries of March 21, 2022, subject to Mr. Singleton's continued employment with the Company through each application vesting date. The exercise price for the options is $13.29. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

07:12 EDT Parker-Hannifin says third party gained unauthorized access to company's systems - On March 14, Parker-Hannifin detected that a third party gained unauthorized access to the company's systems. The company immediately activated incident response protocols, which included shutting down certain systems and commencing an investigation of the incident, which is ongoing. The company also notified and is working with relevant law enforcement authorities, and engaged legal counsel and other third-party incident response and cybersecurity professionals. While the company's investigation is ongoing, the company believes some data was accessed and taken and may include personal information of company team members. Based on its preliminary assessment and on the information currently known, the incident has not had a significant financial or operational impact and the company does not believe the incident will have a material impact on its business, operations or financial results. The company's business systems are fully operational, and the company maintains insurance, subject to certain deductibles and policy limitations typical for its size and industry.

07:11 EDT Twist Bioscience, Ginkgo Bioworks announce new supply agreement - Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) announced a new supply agreement expanding the depth and breadth of the collaboration between two of the organizations in the synthetic biology ecosystem. The four-year agreement includes an increased commitment by Ginkgo to purchase products from Twist, with the option to access significantly more synthesis capacity to meet Ginkgo's anticipated growth. The partnership builds on a previous supply agreement signed in 2017.

07:10 EDT Tonix extends sponsored research agreement with Kansas State University - Tonix Pharmaceuticals Holding announced a new preclinical research agreement with Kansas State University to extend the research being performed under its original agreement. Tonix and K-State are working together to develop a vaccine candidate for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform, bovine parainfluenza virus, and also to test the effect of co-expression of the CD40-ligand, also known as CD154 or 5c8 antigen, to stimulate T cell immunity. Under the extended research agreement, K-State will continue to advance preclinical development of a live replicating virus vaccine to protect against COVID-19 based on bovine parainfluenza virus and also to test the effect of co-expression of the CD40-ligand. Attenuated bovine parainfluenza virus has previously been shown to be an effective antigen delivery vector in humans. Notably and most importantly, following extensive testing in non-human primates, the attenuated BPI3V was shown to be well tolerated, infectious, immunogenic, and stable in infants and children. The vector is well suited for mucosal immunization using a nasal atomizer, but it can also be delivered parenterally. The technology also includes a molecular stimulant called CD40-ligand, which triggers strong immunity, including T cell responses. TNX-2300 is designed to potentially stimulate immunity against the SARS-CoV-2 spike protein. The research is being directed by Dr. Waithaka Mwangi, Kansas State University, Department of Diagnostic Medicine/Pathobiology, who is the inventor of the new technology. In addition, K-State has granted Tonix an option for an exclusive license for the clinical and commercial use of K-State's intellectual property associated with coronavirus vaccines under this relationship.

07:08 EDT Universal Stainless & Alloy names DiTommaso as VP, CFO - Universal Stainless & Alloy Products announced that Steven DiTommaso has been named Vice President, VP, and Chief Financial Officer, CFO, of the Company, effective April 1, 2022. DiTommaso has served as Corporate Controller of the Company since 2018, leading the Company's accounting and treasury operations with expanding responsibilities in strategy development and operations.

07:06 EDT Nurix Therapeutics doses first patient in Phase 1 trial of DeTIL-0255 - Nurix Therapeutics announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio. The trial is designed to evaluate the safety and efficacy of DeTIL-0255 in patients with advanced gynecological malignancies including ovarian cancer, cervical cancer, and endometrial cancer. "The initiation of our first cell therapy study is a major milestone for Nurix and the culmination of significant efforts across our clinical, regulatory and manufacturing teams. It is also the first time targeted protein modulation has been combined with cell therapy, marking the beginning of what we believe will be an important step forward in the treatment of solid tumors," said Robert Brown, M.D., executive vice president of clinical development of Nurix. "Within the rubric of targeted protein modulation, Nurix has now moved three treatment modalities into the clinic including oral targeted protein degraders, an oral CBL-B inhibitor, and now a drug-enhanced cell therapy." CBL-B is an E3 ligase that is expressed in immune cells, and in the context of cancer functions as an intracellular checkpoint that negatively regulates T cell activation, Nurix expects to provide a clinical update from the safety run-in portion of the Phase 1 study in the second half of 2022.

07:06 EDT Ion Geophysical announces agreement for further forbearance extensions - ION Geophysical Corporation announced that it has entered into a Second Amendment to the Second Forbearance extension with the lenders under its Seventh Amendment to the Credit Agreement dated March 8, 2022, pursuant to which the lenders have agreed to extend the current forbearance through April 10, 2022. ION also announced that it had entered into Amendment No. 3 to the Forbearance Agreement with holders of more than 79% of its 2025 Notes to continue their forbearance through April 10, 2022. The forbearances are subject to the terms and conditions of the relevant agreements, which are described in more detail in our current report on Form 8-K filed with the SEC. ION remains in continuing discussions with its lenders and the holders of its 2025 Notes and other indebtedness regarding various strategic alternatives to strengthen its financial position and maximize stakeholder value. These strategic alternatives include, among others, a sale or business combination transaction or sales of assets, any of which may be executed as part of an in-court or out-of-court restructuring process.

07:05 EDT Tiziana Life announces FDA permission to enroll 8 more SPMS patients in trial - Tiziana Life Sciences announced that its collaborators at the Brigham and Women's Hospital, BWH, Boston MA have received a 'Study May Proceed Letter' from the U.S. Food and Drug Administration, FDA, permitting initiation of treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access IND. The safety, tolerability, and clinical responses from the first two SPMS patients were submitted to the FDA to seek permission to treat up to an additional eight SPMS patients with the goal of obtaining more clinical data to assess robustness of the clinical responses. As part of the original treatment plan, the foralumab dose will remain 50 mcg three times a week, which is the same dose administered previously to the first two SPMS patients. The dosing regimen in this IND also has a provision for dose escalation up to 100 mcg three times a week as an option to improve clinical benefit, if needed. The treatment plan will be submitted to the Institutional Review Board, IRB, of BWH prior to initiation of patient enrollment and initiation of the study, which is anticipated to be initiated in July 2022. Howard Weiner, M.D., Director of the Multiple Sclerosis Program at the BWH and Chairman of Tiziana's Scientific Advisory Board, commented, "Treatment with intranasal foralumab is a novel physiological approach to stimulate the mucosal immune system to induce disease-modifying benefits in the CNS by dampening microglial inflammation. The first validation of our innovative approach came from our recently reported results showing positive clinical benefits and microglial modulation in a patient with secondary progressive multiple sclerosis who was treated for six months with nasal Foralumab3. This now opens the door to treat other neurologic diseases which have microglial inflammation - such as Alzheimer's disease - with intranasal foralumab. "

07:04 EDT Oncorus extends cash runway into early 2024

07:03 EDT Hut 8 Mining reports 345 Bitcoin mined in March - Hut 8 Mining advanced its Bitcoin holdings in the period ending March 31. Production highlights for March include 345 Bitcoin were mined, resulting in an average production rate of 11.1 Bitcoin per day; Ethereum mining generated approximately 13% of total production, at an average cost of less than C$2,600 per Bitcoin; 100% of the self-mined Bitcoin for the month of March were deposited into custody, consistent with Hut 8's HODL strategy; total Bitcoin balance held in reserve is 6,460 as of March 31; installed operating capacity currently sits at 2.54 EH/s.

07:02 EDT Eliem Therapeutics appoints Susan Franks as SVP, head of regulatory affairs - Eliem Therapeutics announced the strengthening of its executive team with the appointment of Susan Franks, MS as Eliem's Senior Vice President and Head of Regulatory Affairs. Franks most recently served as the Senior Vice President and Head of Regulatory Affairs at Braeburn Inc., where she was responsible for managing the regulatory team with a focus on its opioid use disorder and pain pipeline.

06:58 EDT Bristol-Myers announces EC approval of Opdivo combined with fluoropyrimidine - Bristol Myers Squibb announced that the European Commission, or EC, has approved Opdivo, or nivolumab, in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma, or ESCC, with tumor cell PD-L1 expression greater than or equal to 1%. The EC's decision is based on results from the Phase 3 CheckMate -648 trial, in which Opdivo with chemotherapy demonstrated a statistically significant and clinically meaningful overall survival benefit compared to chemotherapy alone at the pre-specified interim analysis. The safety profile of Opdivo with chemotherapy was consistent with previously reported studies. Results from CheckMate -648 were presented at the American Society of Clinical Oncology Annual Meeting in June 2021.

06:57 EDT SBM Offshore awarded contracts for Exxon Mobil FPSO One Guyana - SBM Offshore (SBFFF) announced that Esso Exploration and Production Guyana Limited, or EEPGL, an affiliate of Exxon Mobil (XOM), has confirmed the award of contracts for the Yellowtail development project located in the Stabroek Block in Guyana. Under these contracts, SBM Offshore will construct, install and then lease and operate the One Guyana FPSO for a period of up to two years, after which the FPSO ownership and operation will transfer to EEPGL. The award follows completion of front-end engineering and design studies, receipt of requisite government approvals and the final investment decision on the project by ExxonMobil and block co-venturers. The Yellowtail development is the fourth development within the Stabroek block, circa 200 kilometers offshore Guyana. EEPGL is the operator and holds a 45% interest in the Stabroek block, Hess Guyana Exploration (HES) holds a 30% interest and Cnooc Petroleum Guyana (CEO) holds a 25% interest. SBM Offshore is committed to work with Guyanese companies for work to be performed in Guyana and is preparing to further recruit and employ Guyanese engineers into the project team.

06:53 EDT Merck says cardiovascular portfolio to exceed $10B approaching mid-2030's - Merck will provide a detailed overview of the company's broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors on April 5 starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. Overall peak commercial revenue opportunity for the portfolio, including initial and future indications, is expected to exceed $10B approaching the mid-2030s

06:51 EDT US Foods enters new distribution partnership with Planet Based Foods - Planet Based Foods announced a new distribution partnership with US Foods. The company's plant-based options will be initially distributed by two of US Foods' divisions, La Mirada and Corona, which supply a variety of products to restaurants, business and industry, healthcare and many independent and multi-unit operators throughout the Southern California region. Both divisions will stock The Original Burger, Mild Breakfast Sausage Patties and The Italian Sausage Crumble, while the Green Chili Southwest Burger and Hot Breakfast Sausage Patties will also be available via special order.

06:48 EDT Booz Allen to sell MENA region management consulting business to Oliver Wyman - Oliver Wyman, a business of Marsh McLennan (MMC), announced that it has entered into an agreement to acquire Booz Allen Hamilton's (BAH) management consulting business serving the Middle East and North Africa, or MENA, region. The acquired entity will join Oliver Wyman's India, Middle East and Africa, or IMEA, practice. The transaction is expected to close in 2022 and is subject to customary closing conditions, including regulatory approvals. Terms of the transaction were not disclosed.

06:48 EDT Bristol-Myers receives EC approval for Opdivo as immunotherapy option - Bristol Myers Squibb announced that the European Commission has approved Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression greater than or equal to1% who are at a high risk of recurrence after undergoing radical resection. With this EC decision, Opdivo becomes the first adjuvant immunotherapy option approved for patients in the European Union in this setting. In the Phase 3 CheckMate -274 trial, Opdivo demonstrated a statistically significant and clinically meaningful improvement in disease-free survival compared to placebo in both all-randomized patients and in patients whose tumor cells express PD-L1 greater than or equal to1%. The EC decision is based on the results in patients with tumor cell PD-L1 expression greater than or equal to1%, which showed a 47% reduction in the risk of disease recurrence or death with Opdivo vs. placebo, with median DFS not reached with Opdivo compared to 8.41 months with placebo. Opdivo was generally well tolerated, with a safety profile that was consistent with previously reported Opdivo studies in patients with solid tumors.

06:45 EDT GXO Logistics expands partnership with Harry's - GXO Logistics announced that it is expanding its partnership with Harry's. Since 2019, GXO has supported Harry's growth in Europe, where the U.S.-based manufacturer sells shaving equipment and personal care products through online and retail channels. GXO will further optimize Harry's e-commerce and retail operations and provide flexibility to manage large volumes during seasonal peaks. GXO's facilities also support Harry's value-added services, including promotional kitting and personalized engraving.

06:42 EDT Bottomline Technologies announces NatWest adoption of CoP solution - Bottomline announced the NatWest Group has adopted Bottomline's Confirmation of Payee, or CoP, solution to service their Agency Institutions in the fight against authorized push payment fraud across the UK.

06:41 EDT Exfo announces U.S. MNO chooses to deploy Nova Active testing capabilities - Exfo announced a Tier 1 U.S. mobile network operator, or MNO, has chosen to deploy Exfo's Nova Active testing capabilities across their 5G network from core to edge to last mile, helping provide ultra-fast, ultra-reliable connections for customers. Results of synthetic network tests from Nova Active will be paired with EXFO's Nova SensAI software-already deployed with the MNO-to diagnose customer-impacting performance issues in real time and to reduce troubleshooting mean time to repair.

06:36 EDT MarketAxess reports March trading volume $894.6B, its second highest - MarketAxess Holdings announced monthly trading volume for March of $894.6B, consisting of $285.1B in credit volume and $609.5B in rates volume. "We achieved the second highest level of monthly total trading volume in March, and record quarterly total trading volume, surpassing the high-water mark set in the first quarter of 2020 at the height of the pandemic. These strong results include record quarterly emerging markets, municipal bond and U.S. Treasury volume, reflecting the powerful diversification of our global marketplace," commented Rick McVey, Chairman and CEO of MarketAxess. The Company also reported preliminary variable transaction fees per million for the quarter ended March 31 of $154 for U.S. high-grade, $188 for other credit, $172 for total credit and $3.80 for rates. The FPM for the quarter ended March 31, 2022 are preliminary and may be revised in subsequent updates and public filings.

06:33 EDT Trilogy Metals welcomes invoking of DPA - Trilogy Metals announced that it welcomes the recent announcement by President Biden invoking the Defense Production Act, or DPA. The company said, "The DPA is an aggressive measure to increase the US domestic production of metals including cobalt, nickel, lithium, manganese, and graphite. The DPA is a Cold War-era statute that gives the President access to funding and other enhanced powers to shore up the American industrial base and ensure the private sector has the necessary resources to defend national security and face emergencies." Tony Giardini, President and CEO of Trilogy, commented, "With the statement by President Biden specifically highlighting that the United States needs to end its long-term reliance on adversarial countries for metals that are critical to a green economy, we want to reiterate that the Upper Kobuk Mineral Projects ("UKMP") hosts Indicated Resources of 3.4 billion pounds of copper and 3.4 billion pounds of zinc, and Inferred Resources of 5.4 billion pounds of copper and 88 million pounds of cobalt1. We believe that the resources at the UKMP will become a critical source of green metals for the US economy, as well as a significant economic contributor within the Northwest Arctic Borough, its Native communities, and the Alaskan economy."

06:31 EDT Babcock & Wilcox awarded $12M contract by Lotte Engineering & Construction - Babcock & Wilcox announced that its B&W Environmental segment has been awarded a contract for more than $12M by Lotte Engineering & Construction to supply hybrid cooling systems for Korea District Heating Corporation's power generation and district heating projects in Daegu and Cheongju, South Korea. B&W Environmental will design and supply two SPIGTM hybrid cooling towers that utilize advanced wet and dry cooling technologies to efficiently cool the plants while reducing water consumption, minimizing plume formation and decreasing noise emissions.

06:29 EDT Visa, PopID announce facial verification payment acceptance partnership - PopID and Visa announced a partnership to collaborate on launching facial verification payment acceptance in the Middle East region. The goal of the partnership is to provide cardholders with new safe, secure, and innovative ways to pay.

06:05 EDT ESAB completes separation from Enovis, to begin trading on April 5 - ESAB (ESAB) announced the completion of its separation from Enovis, formerly known as Colfax (CFX), and its launch as an independent, publicly traded corporation. ESAB's common stock will begin trading "regular way" on April 5, on the New York Stock Exchange under the symbol "ESAB."

06:02 EDT Change Healthcare and Optum extend merger agreement - Optum and Change Healthcare have agreed to extend their merger agreement to December 31. In a joint statement, the companies said: "The extended agreement reflects our firm belief in the potential of our combination to improve health care, and in our commitment to contesting the meritless legal challenge to this merger." Change Healthcare and Optum will detail the benefits of this combination at a two-week trial scheduled to begin on August 1. The U.S. Department of Justice's attempt to block the combination is without merit and serves only to delay improving the experience and outcomes for all participants in the health system. As part of the extension, Optum will pay a $650M fee to Change Healthcare in the event the merger is unable to be completed because of the court's decision. Change Healthcare will pay a special cash dividend of $2.00 per share to its shareholders at or about the time of the closing.